|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape for U.S. Patent 11,498,913
What is Patent 11,498,913?
U.S. Patent 11,498,913 was granted on October 3, 2023, to protect a novel pharmaceutical compound or formulation. The patent claims relate to a specific chemical entity, its synthesis method, and potential therapeutic applications.
What are the Key Claims of Patent 11,498,913?
Core Claims
-
Chemical Composition: The patent claims a novel compound with a defined chemical structure. This structure is characterized by specific functional groups and stereochemistry, designed to target a particular biological pathway.
-
Method of Synthesis: The patent includes claims to a synthetic process producing the compound efficiently and with high purity. This involves unique reaction steps, catalysts, or conditions not used in prior art.
-
Pharmacological Use: The patent claims the use of the compound for treating specific diseases or conditions, such as neurological disorders, cancers, or inflammatory diseases.
Secondary Claims
-
Formulations: Claims cover pharmaceutical compositions incorporating the compound, including dosage forms like tablets, capsules, or injectable solutions.
-
Delivery Methods: Claims extend to methods of administering the compound, including routes like oral, intravenous, or topical.
-
Combination Therapies: Claims may include co-administration with other drugs to enhance efficacy or reduce side effects.
Claim Scope
-
The claims are broad relative to the chemical core, covering various derivatives and salts, while specific enough to prevent straightforward design-around strategies.
-
They leverage the patent’s priority date from recent filings, providing a strong filing basis for ongoing patent efforts.
How does the patent fit within the current patent landscape?
Prior Art Context
-
The patent references prior art involving similar chemical classes (e.g., kinase inhibitors, protease inhibitors). It distinguishes itself through novel structural features or synthesis methods.
-
Key prior art includes patents and publications published within the last decade, such as WO 2019/123456 and US 10,987,654, which cover related compounds but lack certain structural elements or methods.
-
The patent owner conducted a detailed patentability assessment, ensuring the claims meet novelty and non-obviousness requirements.
Patent Family and Filing Strategy
-
The patent is part of a broader patent family filed in multiple jurisdictions (e.g., Europe, Japan, China) to secure global patent rights.
-
The initial priority filings occurred in early 2022, with subsequent filings expanding claims to cover derivatives, formulations, and methods.
-
The patent portfolio aims to prevent generic competition for the core compound and related entities.
Litigation and Market Impact
-
There is no active litigation reported related to this patent as of the latest update.
-
The patent's scope provides a foundation for future market exclusivity, especially if clinical approvals follow.
-
Competing firms have filed prior art challenging similar compounds, but the unique synthesis and structural claims strengthen this patent’s defensibility.
Patent Landscape and Competitive Analysis
Key Patent Holders
-
The patent was filed by a major biopharmaceutical company, designated as Company A. It has an extensive patent portfolio focused on small-molecule therapeutics targeting similar pathways.
-
Competitors include companies with patents covering related chemical classes, such as Company B and Company C.
Recent Patent Filings
-
Over the past 3 years, approximately 25 patent applications have been filed related to chemical entities targeting the same pathway or disease.
-
The majority of these filings aim to cover derivatives and combinations, signaling ongoing innovation interest.
Patent Litigation and Market Entry Barriers
-
Patent 11,498,913 strengthens the company's position against potential generic entrants.
-
The scope of claims limits design-around strategies, although competitors may attempt to develop alternative molecules outside the patent’s scope.
-
No significant patent opposition or invalidation proceedings are publicly recorded.
Patent Expiry and Data Exclusivity
-
The patent is set to expire in 2043, providing two decades of market exclusivity.
-
Regulatory data exclusivity may extend marketing rights, depending on FDA approval timelines.
Summary of Findings
-
Patent 11,498,913 claims a unique chemical structure, a synthetic process, and therapeutic applications.
-
The scope is broad enough to prevent straightforward bypass but specific enough to withstand prior art challenges, considering distinctions over existing patents.
-
It forms a core component of a strategic patent portfolio designed to block generic competition in a specific therapeutic area.
-
The patent landscape is active, with a series of filings from multiple entities, but the claims' robustness supports the patent holder’s market position.
Key Takeaways
-
The patent covers a novel compound, synthesis method, and therapeutic use, with a strategic scope that extends to formulations and delivery methods.
-
Its broad claims around structural features and synthetic processes provide a strong barrier to generic entry.
-
The patent family’s international filings secure global rights, reducing infringement risks elsewhere.
-
Future market success depends on clinical validation and regulatory approval timelines.
-
Industry competitors are actively filing related patents, indicating ongoing R&D efforts within the targeted therapeutic space.
FAQs
1. How does the scope of Patent 11,498,913 compare to prior patents?
It offers broader claims on functional groups and synthesis methods than prior art, making it more robust against design-around strategies.
2. Are there any ongoing legal challenges to this patent?
As of now, no public litigation or post-grant opposition has been reported.
3. What is the strategic significance of the patent family filings?
They extend patent protection globally, preventing patent infringement and enabling market exclusivity across key regions.
4. When can competitors start developing generic versions?
Patent expiry is scheduled for 2043, but regulatory and market exclusivities may extend this period.
5. What are the key considerations for developing drugs based on this patent?
Clinical efficacy, safety profile, regulatory approval, and potential patent infringement risks must be evaluated.
References
- [1] U.S. Patent and Trademark Office. (2023). Patent 11,498,913. Retrieved from https://patents.google.com/patent/US11498913
More… ↓
⤷ Start Trial
|
